Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16783495 | 0.82 | ENPP2 (0.32) | PDGFRBKDR | |
| SCHEMBL427156 | 0.78 | CA2 (0.33) | PDGFRBKDR | |
| SCHEMBL16618253 | 0.78 | TTR (0.38) | — | |
| SCHEMBL17420983 | 0.78 | VRK1 (0.38) | PDGFRBKDR | |
| SCHEMBL14121768 | 0.78 | KEAP1 (0.33) | — | |
| SCHEMBL25346943 | 0.78 | PDGFRB (0.40) | PDGFRBKDR | |
| SCHEMBL29825823 | 0.78 | CA2 (0.33) | PDGFRBKDR | |
| SCHEMBL29953245 | 0.78 | KDM4E (0.33) | PDGFRBKDR | |
| SCHEMBL29955519 | 0.78 | KEAP1 (0.33) | — | |
| SCHEMBL17987023 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122079880-A | Nitrogen-containing heterocyclic derivative inhibitor, preparation method and application thereof | — | 2026-05-26 | — | — | CN | disclosed |
| CN-122079879-A | Nitrogen-containing heterocyclic derivative inhibitor, preparation method and application thereof | — | 2026-05-26 | — | — | CN | disclosed |
| CN-122079878-A | Nitrogen-containing heterocyclic derivative inhibitor, preparation method and application thereof | — | 2026-05-26 | — | — | CN | disclosed |
| US-20260085045-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI HANSOH BIOMEDICAL CO LTD (CN) | 2026-03-26 | — | — | US | disclosed |
| EP-4702021-A1 | COMPOUNDS CAPABLE OF MODULATING GPR65 | Pathios Therapeutics Limited (GB) | 2026-03-04 | — | — | EP | disclosed |
| EP-4665453-A1 | GPR65 MODULATORS | Pathios Therapeutics Limited (GB) | 2025-12-24 | — | — | EP | disclosed |
| US-12497366-B2 | Nitrogen-containing heterocyclic derivative inhibitor, preparation method therefor and use thereof | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2025-12-16 | — | — | US | disclosed |
| EP-4588914-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2025-07-23 | — | — | EP | disclosed |
| WO-2025149498-A1 | BENZYLPIPERIDINE DERIVATIVES AS TRP4 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | ASTRAZENECA AB (SE) | 2025-07-17 | — | — | WO | disclosed |
| CN-120019043-A | Nitrogen-containing heterocyclic derivative inhibitor, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2025-05-16 | — | — | CN | disclosed |
| WO-2017011776-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA, INC. (US) | 2017-01-19 | — | — | WO | disclosed |
| US-20160251361-A1 | IMIDAZOPYRIMIDINE AND IMIDAZOTRIAZINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2016-09-01 | — | — | US | disclosed |
| WO-2016137260-A1 | IMIDAZOPYRIMIDINE AND IMIDAZOTRIAZINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2016-09-01 | — | — | WO | disclosed |
| US-9309243-B2 | Imidazopyridine derivatives as modulators of TNF activity | UCB BIOPHARMA SPRL (BE) | 2016-04-12 | — | — | US | disclosed |
| US-20160060273-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-03-03 | — | — | US | disclosed |
| EP-2970331-A1 | SPIRO AZETIDINE ISOXAZOLE DERIVATIVES AND THEIR USE AS SSTR5 ANTAGONISTS | Takeda Pharmaceutical Company Limited (JP) | 2016-01-20 | — | — | EP | disclosed |
| US-20150203486-A1 | Imidazopyridine Derivatives as Modulators of TNF Activity | UCB Biopharma SPRL a corporation | 2015-07-23 | — | — | US | disclosed |
| EP-2872508-A1 | IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SPRL (BE) | 2015-05-20 | — | — | EP | disclosed |
| WO-2014142363-A1 | SPIRO AZETIDINE ISOXAZOLE DERIVATIVES AND THEIR USE AS SSTR5 ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014009295-A1 | IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB PHARMA S.A. (BE) | 2014-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150203486-A1 | Imidazopyridine Derivatives as Modulators of TNF Activity | TNF, TNFRSF1A, IL1A | BACE1 2758/4885PDGFRB 520/4885KDR 417/4885 |
| US-20160060273-A1 | HETEROCYCLIC COMPOUND | SSTR5, SSTR1, SSTR2 | BACE1 1310/4885PDGFRB 1024/4885KDR 985/4885 |
| US-20260085045-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | NPR1, CBR1, NAT1 | BACE1 240/4885PDGFRB 1678/4885KDR 346/4885 |
| US-20160251361-A1 | IMIDAZOPYRIMIDINE AND IMIDAZOTRIAZINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | GRM5, GRIK5, GRM1 | BACE1 3721/4885PDGFRB 2375/4885KDR 2906/4885 |
| US-12497366-B2 | Nitrogen-containing heterocyclic derivative inhibitor, preparation method therefor and use thereof | WEE1, WEE2, NOS1 | BACE1 127/4885PDGFRB 1125/4885KDR 909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.